1 - 25 of 74 results for author:"Haber D.A." in Literature citations
Results Customize
› Repeat search in UniProtKB (61)
| An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Mitra D., Luo X., Morgan A., Wang J., Hoang M.P., Lo J., Guerrero C.R., Lennerz J.K., Mihm M.C., Wargo J.A. et al. Nature 491:449-453(2012) · Mapped (17) |
| RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Yu M., Ting D.T., Stott S.L., Wittner B.S., Ozsolak F., Paul S., Ciciliano J.C., Smas M.E., Winokur D., Gilman A.J. et al. Nature 487:510-513(2012) · Mapped (6) |
| TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Singh A., Sweeney M.F., Yu M., Burger A., Greninger P., Benes C., Haber D.A., Settleman J. Cell 148:639-650(2012) · Mapped (13) |
| The WTX tumor suppressor enhances p53 acetylation by CBP/p300. Kim W.J., Rivera M.N., Coffman E.J., Haber D.A. Mol. Cell 45:587-597(2012) · Mapped (1) |
| Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Chiba N., Comaills V., Shiotani B., Takahashi F., Shimada T., Tajima K., Winokur D., Hayashida T., Willers H., Brachtel E. et al. Proc. Natl. Acad. Sci. U.S.A. 109:2760-2765(2012) · Mapped (2) |
| The WTX tumor suppressor regulates mesenchymal progenitor cell fate specification. Moisan A., Rivera M.N., Lotinun S., Akhavanfard S., Coffman E.J., Cook E.B., Stoykova S., Mukherjee S., Schoonmaker J.A., Burger A. et al. Dev. Cell 20:583-596(2011) · Mapped (93) |
| Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Ting D.T., Lipson D., Paul S., Brannigan B.W., Akhavanfard S., Coffman E.J., Contino G., Deshpande V., Iafrate A.J., Letovsky S. et al. Science 331:593-596(2011) · Mapped (17) |
| YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Zhang J., Ji J.Y., Yu M., Overholtzer M., Smolen G.A., Wang R., Brugge J.S., Dyson N.J., Haber D.A. Nat. Cell Biol. 11:1444-1450(2009) · Mapped (292) |
| Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin. Zhang J., Song Y.H., Brannigan B.W., Wahrer D.C., Schiripo T.A., Harris P.L., Haserlat S.M., Ulkus L.E., Shannon K.M., Garber J.E. et al. Mol. Cancer Res. 7:1510-1516(2009) · Mapped (3) |
| A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Yu M., Smolen G.A., Zhang J., Wittner B., Schott B.J., Brachtel E., Ramaswamy S., Maheswaran S., Haber D.A. Genes Dev. 23:1737-1742(2009) · Mapped (16) |
| The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Rivera M.N., Kim W.J., Wells J., Stone A., Burger A., Coffman E.J., Zhang J., Haber D.A. Proc. Natl. Acad. Sci. U.S.A. 106:8338-8343(2009) · UniProtKB (2) |
| In vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2. Kim S., Mohapatra G., Haber D.A. Br. J. Cancer 99:1302-1306(2008) · Mapped (21) |
| Modeling oncogene addiction using RNA interference. Rothenberg S.M., Engelman J.A., Le S., Riese D.J., Haber D.A., Settleman J. Proc. Natl. Acad. Sci. U.S.A. 105:12480-12484(2008) · Mapped (19) |
| Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Bell D.W., Brannigan B.W., Matsuo K., Finkelstein D.M., Sordella R., Settleman J., Mitsudomi T., Haber D.A. Clin. Cancer Res. 14:4079-4084(2008) · Mapped (66) |
| Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites. Diederichs S., Jung S., Rothenberg S.M., Smolen G.A., Mlody B.G., Haber D.A. Proc. Natl. Acad. Sci. U.S.A. 105:9284-9289(2008) · Mapped (2) |
| Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor. Li H., Smolen G.A., Beers L.F., Xia L., Gerald W., Wang J., Haber D.A., Lee S.B. PLoS ONE 3:e2353-e2353(2008) · Mapped (2) |
| First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., Joshi V.A., McCollum D., Evans T.L., Muzikansky A. et al. J. Clin. Oncol. 26:2442-2449(2008) · Mapped (19) |
| Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. McDermott U., Iafrate A.J., Gray N.S., Shioda T., Classon M., Maheswaran S., Zhou W., Choi H.G., Smith S.L., Dowell L. et al. Cancer Res. 68:3389-3395(2008) · Mapped (18) |
| The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Godin-Heymann N., Ulkus L., Brannigan B.W., McDermott U., Lamb J., Maheswaran S., Settleman J., Haber D.A. Mol. Cancer Ther. 7:874-879(2008) · Mapped (19) |
| Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Zhang J., Smolen G.A., Haber D.A. Cancer Res. 68:2789-2794(2008) · Mapped (14) |
| Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Kim W.J., Okimoto R.A., Purton L.E., Goodwin M., Haserlat S.M., Dayyani F., Sweetser D.A., McClatchey A.I., Bernard O.A., Look A.T. et al. Blood 111:4716-4722(2008) · Mapped (6) |
| Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Diederichs S., Haber D.A. Cell 131:1097-1108(2007) · Mapped (3) |
| Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Bell D.W., Kim S.H., Godwin A.K., Schiripo T.A., Harris P.L., Haserlat S.M., Wahrer D.C., Haiman C.A., Daly M.B., Niendorf K.B. et al. Int. J. Cancer 121:2661-2667(2007) · Mapped (3) |
| A Rap GTPase interactor, RADIL, mediates migration of neural crest precursors. Smolen G.A., Schott B.J., Stewart R.A., Diederichs S., Muir B., Provencher H.L., Look A.T., Sgroi D.C., Peterson R.T., Haber D.A. |
| Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Godin-Heymann N., Bryant I., Rivera M.N., Ulkus L., Bell D.W., Riese D.J., Settleman J., Haber D.A. Cancer Res. 67:7319-7326(2007) · Mapped (19) |